SC3499 / Korea Kolmar, Dong-A - LARVOL DELTA

Rationally designed allosteric EGFR degrader SC3499 (IN-207375) selectively eliminates mutant EGFR and overcomes osimertinib resistance in non-small cell lung cancer (AACR 2026) - "Broad kinase profiling showed exceptional kinase selectivity, and global proteomic analysis confirmed selective degradation of mutant EGFR without affecting unrelated proteins or other cereblon (CRBN) substrates. These results support SC3499 as a promising, orally active, allosteric EGFR degrader capable of overcoming resistance to current EGFR-targeted therapies, including osimertinib, and providing durable antitumor responses in EGFR-mutant NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CRBN • EGFR